Integrating Wnt/β-catenin reporter assays with PI3K signaling effector activity could provide further clarification of the mechanistic differences in PI3K and Wnt/β-catenin crosstalk in different breast cancer subtypes. This evidence concerns the gene PIK3CA and breast cancer.